Andre Esteva: The ArteraAI, Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patient
Andre Esteva, at
“The ArteraAI , Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patients.
To propel adoption, we’ve integrated with PathNetLab, a fully digital pathology lab that serves about 10% of the annual US prostate cancer volume across 200+ clinics in 27 states.
Our test report will now be delivered with immediate turnaround time to clinicians – at the same time as the diagnostic pathology report.
This is in addition to being the only predictive test in the National Comprehensive Cancer Network guidelines, and being reimbursed by Medicare Gov.
About 40% of localized prostate cancer patients are NCCN low-risk.
In these patients the key clinical decision that needs to be made is whether to put them on active surveillance or active treatment.
And if you don’t need treatment, you certainly don’t want to be placed on it.
Artera’s test has been updated to help inform clinicians and patients whether they would benefit from active treatment vs surveillance.
It is a privilege to work with PathNetLab
and its founder Adam Cole to support prostate cancer patients at scale. Interested clinicians can order our test at ArteraAI.”
Source: Andre Esteva/X